Get the Stockscreener App
7.04
2.36%
-0.17
After Hours:
29.72
22.68
+322.16%
Relmada Therapeutics Inc stock is traded at $7.04, with a volume of 668.68K.
It is down -2.36% in the last 24 hours and down -0.28% over the past month.
Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.
See More
Previous Close:
$7.21
Open:
$7.26
24h Volume:
668.68K
Relative Volume:
0.37
Market Cap:
$738.43M
Revenue:
-
Net Income/Loss:
$-57.39M
P/E Ratio:
-4.7898
EPS:
-1.4698
Net Cash Flow:
$-45.79M
1W Performance:
+2.03%
1M Performance:
-0.28%
6M Performance:
+64.87%
1Y Performance:
+1,045%
1-Day Range:
$7.0111
$7.50
1-Week Range:
$6.17
$7.50
52-Week Range:
$0.52
$8.00
Relmada Therapeutics Inc Stock (RLMD) Company Profile
Name
Relmada Therapeutics Inc
Sector
Industry
Phone
646 876 3459
Address
2222 PONCE DE LEON BLVD. 3RD FLOOR, CORAL GABLES, NY
Compare RLMD vs MOBBW, SHMD, GOODO, PSNYW, DWLD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| 3.03 | 0 | 0 | 0 | 0 | 0.00 | |
MOBBW
Mobilicom Limited Warrants
|
2.21 | 2.92B | 0 | 0 | 0 | 0.00 |
SHMD
Schmid Group N V
|
7.49 | 430.62M | 52.15M | -21.46M | 0 | -0.4675 |
GOODO
Gladstone Commercial Corporation
|
20.20 | 372.90M | 0 | 0 | 0 | 0.00 |
PSNYW
Polestar Automotive Holding Uk
|
3.12 | 290.00M | 2.07B | -1.42B | -1.37B | -0.6765 |
DWLD
Davis Select Worldwide ETF
|
46.89 | 0 | 0 | 0 | 0 | 0.00 |
Relmada Therapeutics Inc Stock (RLMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-24-26 | Initiated | Piper Sandler | Overweight |
| Jan-23-26 | Resumed | Leerink Partners | Outperform |
| Dec-22-25 | Initiated | Jefferies | Buy |
| Nov-19-25 | Upgrade | Mizuho | Neutral → Outperform |
| Dec-05-24 | Downgrade | Mizuho | Outperform → Neutral |
| Sep-17-24 | Upgrade | Jefferies | Hold → Buy |
| Jun-05-24 | Downgrade | Goldman | Neutral → Sell |
| Oct-14-22 | Downgrade | Goldman | Buy → Neutral |
| Oct-14-22 | Downgrade | Guggenheim | Buy → Neutral |
| Oct-14-22 | Downgrade | Truist | Buy → Hold |
| Oct-13-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Nov-18-21 | Initiated | Mizuho | Buy |
| May-20-21 | Resumed | Goldman | Buy |
| Oct-28-20 | Downgrade | Goldman | Buy → Neutral |
| Jul-14-20 | Initiated | Oppenheimer | Outperform |
| May-04-20 | Initiated | SunTrust | Buy |
| Apr-21-20 | Initiated | Goldman | Buy |
| Jan-27-20 | Initiated | Jefferies | Buy |
| Jan-10-20 | Initiated | SVB Leerink | Outperform |
| Dec-16-19 | Initiated | Guggenheim | Buy |
View All
Relmada Therapeutics Inc Stock (RLMD) Latest News
RLMD Stock Chart | RELMADA THERAPEUTICS INC (NASDAQ:RLMD) - ChartMill
Earnings call transcript: Relmada Therapeutics Q1 2026 sees stock dip despite strong cash position By Investing.com - Investing.com South Africa
Earnings call transcript: Relmada Therapeutics Q1 2026 sees stock dip despite strong cash position - Investing.com
Relmada Therapeutics, Inc.Common Stock (NQ: RLMD - FinancialContent
Relmada targets mid-2026 phase 3 RESCUE start backed by $234M cash runway through 2029 - MSN
Wall Street analysts predict a 92.19% upside in Relmada Therapeutics (RLMD): Here's what you should know - MSN
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Relmada Therapeutics Charts Ambitious NDV-01 Phase 3 Path - TipRanks
Relmada Therapeutics Inc files for mixed shelf offering, size not disclosedSEC filing - marketscreener.com
Relmada Therapeutics Q1 earnings call highlights - MSN
Relmada Therapeutics (NASDAQ: RLMD) registers 29.5M shares tied to $160M deal - Stock Titan
Relmada Therapeutics Q1 Loss per Share Narrows - Moomoo
Adage Capital reports 4.54% stake in Relmada Therapeutics (NASDAQ: RLMD) - Stock Titan
Q1 2026 Relmada Therapeutics Inc Earnings Call Transcript - GuruFocus
Piper Sandler Maintains Relmada Therapeutics(RLMD.US) With Buy Rating, Maintains Target Price $12 - Moomoo
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q1 2026 Earnings Call Transcript - Insider Monkey
Relmada Therapeutics Reports Strong Q1 2026 Results, Highlights Positive NDV-01 Phase 2 Data in Bladder Cancer and Plans for Phase 3 RESCUE Program - Minichart
Relmada Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update - The Manila Times
Relmada Therapeutics Inc (RLMD) Q1 2026 Earnings Call Highlights - GuruFocus
Is Relmada Therapeutics (RLMD) Fairly Valued After Q1 2026? EPS: - GuruFocus
Relmada Therapeutics Q1 Earnings Call Highlights - sharewise.com
Transcript : Relmada Therapeutics, Inc., Q1 2026 Earnings Call, May 12, 2026 - marketscreener.com
Relmada Highlights NDV-01 Phase 2 Data, Phase 3 Plans - TipRanks
Earnings call transcript: Relmada Therapeutics Q1 2026 results reveal mixed performance - Investing.com Nigeria
RLMD: NDV-01 shows best-in-class efficacy in NMIBC; cash and patent position support long-term growth - TradingView
RLMD: NDV-01 demonstrates high efficacy in NMIBC, with robust financials supporting late-stage trials - TradingView
Transcript: Relmada Therapeutics Q1 2026 Earnings Conference Call - Benzinga
Relmada (NASDAQ: RLMD) boosts cash with $160M PIPE and NDV-01 data - Stock Titan
RLMD: NDV-01 demonstrates high response rates in NMIBC, with pivotal trials and strong financial backing ahead - TradingView
RELMADA THERAPEUTICS ($RLMD) Releases Q1 2026 Earnings - Quiver Quantitative
RLMD: Robust NDV-01 Phase 2 results and $160M financing support Phase 3 launch and long-term funding - TradingView
Relmada Therapeutics Q1 net loss widens, cash rises - TradingView
Earnings Flash (RLMD) Relmada Therapeutics Posts Q1 Loss $0.22, vs. FactSet Est of $0.20 Loss - marketscreener.com
Relmada Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Relmada Therapeutics (NASDAQ: RLMD) posts Q1 loss, builds cash for NDV-01, sepranolone - Stock Titan
Relmada Therapeutics Q1 2026 Earnings Call Transcript - MarketBeat
TradingKey - TradingKey
Relmada Therapeutics to Report First Quarter 2026 Financial Results on Tuesday, May 12, 2026 - Investing News Network
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Relmada Therapeutics Inc expected to post a loss of 19 cents a shareEarnings Preview - TradingView
Number of shareholders of Relmada Therapeutics Inc – MUN:4E2 - TradingView
Q2 2025 Relmada Therapeutics Inc Earnings Call Transcript - GuruFocus
Q3 2025 Relmada Therapeutics Inc Earnings Call Transcript - GuruFocus
Relmada Therapeutics to Announce First Quarter 2026 Financial Results on May 12 - geneonline.com
Biotech Relmada will discuss Q1 results and business update May 12 - Stock Titan
Relmada Therapeutics to Present NDV-01 Abstracts at AUA2026 - Investing News Network
Bladder cancer drug NDV-01 heads to AUA with Phase 3 on track - Stock Titan
Relmada Therapeutics Inc Stock (RLMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Relmada Therapeutics Inc Stock (RLMD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Shenouda Maged | Chief Financial Officer |
Dec 15 '25 |
Buy |
4.12 |
11,665 |
48,060 |
800,000 |
| Shenouda Maged | Chief Financial Officer |
Nov 05 '25 |
Buy |
2.20 |
500,000 |
1,100,000 |
788,335 |
| Ence Chuck | CAO and COO |
Nov 05 '25 |
Buy |
2.20 |
136,000 |
299,200 |
403,931 |
| TRAVERSA SERGIO | Chief Executive Officer |
Nov 05 '25 |
Buy |
2.20 |
272,500 |
599,500 |
1,272,500 |
| Kelly Paul Edward | Chief Operating Officer |
Nov 05 '25 |
Buy |
2.20 |
90,000 |
198,000 |
502,295 |
| TRAVERSA SERGIO | Chief Executive Officer |
Aug 27 '25 |
Buy |
0.67 |
129,455 |
86,735 |
944,024 |
| TRAVERSA SERGIO | Chief Executive Officer |
Aug 26 '25 |
Buy |
0.62 |
80,545 |
49,938 |
814,569 |
| TRAVERSA SERGIO | Chief Executive Officer |
Aug 28 '25 |
Buy |
0.74 |
55,976 |
41,422 |
1,000,000 |
2.98%
1.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):